Scott K. Heysell, MD, MPH
Research Interests: Multidrug resistant tuberculosis (MDR-TB);
pharmacokinetics; clinical application of diagnostics for TB; clinical
trials to optimize TB treatment
Dr. Heysell has prior field experience living in HIV/drug-resistant TB endemic areas including rural South Africa (Tugela Ferry) during post-doctoral training in Tropical Infectious Diseases from Yale University, and currently in the Kilimanjaro region of Tanzania. While in Tanzania, he consults at the national drug-resistant TB hospital, Kibong’oto, and partners with investigators at the Kilimanjaro Clinical Research Institute. His research focuses on the understanding of anti-TB pharmacokinetics and the application of novel M. tuberculosis susceptibility testing, particularly in patients with multidrug-resistant TB, or with the comorbid conditions of HIV or diabetes. He is currently funded by the NIH and non-governmental foundations for projects in Virginia, Tanzania, Bangladesh and Eastern Siberia.
Heysell SK, Moore JL, Staley D, Dodge D, Houpt ER. Early therapeutic drug monitoring for isoniazid and rifampin among diabetics with newly diagnosed tuberculosis in Virginia, U.S.A. Tuberc Res Treat 2013; epub 10.1155/2013/129723. PMCID: PMC3855970
Banu S, Rahman SMM, Khan MSR, Ferdous S, Ahmed S, Gratz J, Stroup S, Pholwat S, Heysell SK, Houpt ER. Discordance across several drug susceptibility methods for drug-resistant tuberculosis in a single laboratory. J Clin Micro 2014; 52(1): 156-63. PMCID: PMC3911413
Mpagama S, Ndusilo N, Stroup S, Gratz J, Kumburu H, Moore JL, Peloquin CA, Houpt ER, Kibiki GS, Heysell SK*. Plasma drug activity in patients treated for multidrug-resistant tuberculosis. Antimicrob Agents Chemother 2014 Feb;58(2):782-8. *corresponding author. PMCID: PMC3910816
Thomas TA, Heysell SK, Moodley P, Mhlongo P, Solwa Z, Bamber S, Moll A, Montreuil R, Ha X, Gandhi NR, Brant W, Sturm AW, Friedland G, Shah NS. Intensified specimen collection to improve tuberculosis diagnosis in children from rural South Africa, an observational study. BMC Infect Dis 2014; 14(1):11. PMCID: PMC3890632
Reynolds J, Heysell SK. Understanding pharmacokinetics to improve tuberculosis treatment outcome. Expert Opin Drug Metab Toxicol 2014; epub ahead of print. PMCID pending
Thomas TA, Heysell SK, Houpt ER, Moore JL, Keller SJ. Outbreak of pyrazinamide mono-resistant Mycobacterium tuberculosis identified by genotype cluster and social media analysis. Int J Tuberc Lung Dis 2014; 18(5):552–558. PMCID pending
Heysell SK. Having walked the path. Ann Int Med 2014 (narrative); accepted.
|Office Phone:||+1 434-982-1700|
|Office Fax:||+1 434-924-0075|